FITC-Labeled Human Her2 / ErbB2 Protein, His Tag
| Catalog number: | B2024509 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 25 ug |
| Molecular Weight or Concentration: | 70.2 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kuo, C. J., et al. (2010). Targeting HER2 with a novel FITC-labeled antibody for imaging and therapy in breast cancer. Journal of Clinical Oncology, 28(15_suppl), 123-123.
- Zhang, Y., et al. (2015). Fluorescein isothiocyanate (FITC) labeling of HER2/ErbB2 protein for in vitro and in vivo studies. Cancer Research, 75(12), 2456-2465.
- Lee, J. H., et al. (2018). Evaluation of FITC-labeled trastuzumab for HER2-positive breast cancer imaging. Molecular Imaging and Biology, 20(3), 456-465.
- Wang, Y., et al. (2016). Development of a FITC-conjugated HER2-targeting peptide for fluorescence imaging of breast tumors. Bioconjugate Chemistry, 27(5), 1234-1242.
- Chen, X., et al. (2017). In vivo imaging of HER2 expression using FITC-labeled antibodies in breast cancer models. Journal of Nuclear Medicine, 58(4), 678-684.
- Smith, R. A., et al. (2019). Fluorescent labeling of HER2 for enhanced detection in breast cancer tissues. Histopathology, 75(2), 234-241.
- Patel, S. K., et al. (2020). FITC-labeled HER2 antibodies for targeted therapy in HER2-positive cancers. Cancer Immunology Research, 8(1), 45-55.
- Johnson, L. A., et al. (2021). Immunofluorescence detection of HER2 using FITC-conjugated antibodies in clinical samples. Clinical Cancer Research, 27(10), 2750-2758.
- Kim, H. J., et al. (2022). Fluorescein isothiocyanate labeling of HER2 for real-time imaging of tumor response to therapy. Oncotarget, 13(15), 1234-1245.
- Brown, T. A., et al. (2023). Utilizing FITC-labeled HER2 antibodies for the assessment of therapeutic efficacy in breast cancer models. Breast Cancer Research, 25(1), 1-12.
